Zhao Lab

Recent Publications

1.    A versatile system for rapid multiplex genome-edited CAR T cell generation.Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y. Oncotarget. 2017 Mar 7;8(10):17002-17011


2.    Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Clin Cancer Res. 2016 Nov 4


3.    A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK. Cancer Res. 2016 Mar 15;76(6):1578-90. 


4.    Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ Jr. Oncotarget. 2015 Oct 6;6(30):28911-28. 


5.    Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, Zhou L, Loew A, Young RM, June CH, Zhao Y. Cancer Res. 2015 Sep 1;75(17):3596-607.


6.    Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM. Clin Cancer Res. 2016 Jan 15;22(2):436-47. 


7.    Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Cancer Immunol Res. 2014 Nov;2(11):1059-70. 


8.    Engineered T cells for cancer therapy. June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Cancer Immunol Immunother. 2014 Sep;63(9):969-75. 


9.    T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. Cancer Immunol Res. 2013 Jul;1(1):26-31


10.    Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Cancer Immunol Res. 2014 Feb;2(2):112-20. 


11.    Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Cytotherapy. 2014 May;16(5):619-30. 


12.    Adoptive immunotherapy for cancer or viruses. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Annu Rev Immunol. 2014;32:189-225. 


13.    Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Hum Gene Ther. 2013 Aug;24(8):717-27. 


14.    Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, June CH. Hum Gene Ther. 2013 Jan;24(1):27-37. 


15.    TCR affinity and specificity requirements for human regulatory T-cell function. Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, Bennett AD, Gavarret J, Vuidepot A, Zhao Y, Blazar BR, Jakobsen BK, Riley JL. Blood. 2012 Apr 12;119(15):3420-30. 


16.    Treatment of advanced leukemia in mice with mRNA engineered T cells. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA. Hum Gene Ther. 2011 Dec;22(12):1575-86. 


17.    Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Cancer Res. 2010 Nov 15;70(22):9053-61. 


18.    A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. J Immunol. 2009 Nov 1;183(9):5563-74. 


19.    Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. J Clin Invest. 2010 Nov;120(11):3953-68. 


20.    Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.J Immunother. 2009 Sep;32(7):689-702